| Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data |
60 |
| Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study |
39 |
| Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation |
28 |
| NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis |
25 |
| Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) |
24 |
| Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study |
22 |
| CCL17 blockade as a therapy for osteoarthritis pain and disease |
22 |
| The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients |
22 |
| IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis |
21 |
| Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations |
21 |
| Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study |
20 |
| CircIBTK inhibits DNA demethylation and activation of AKT signaling pathway via miR-29b in peripheral blood mononuclear cells in systemic lupus erythematosus |
17 |
| The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis |
17 |
| Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue |
17 |
| Enhanced IL-6/phosphorylated STAT3 signaling is related to the imbalance of circulating T follicular helper/T follicular regulatory cells in patients with rheumatoid arthritis |
16 |
| Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS) |
16 |
| Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study |
16 |
| Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease |
16 |
| Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women |
15 |
| Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature |
15 |
| Curcumin attenuates MSU crystal-induced inflammation by inhibiting the degradation of I kappa B alpha and blocking mitochondrial damage |
15 |
| Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease |
14 |
| Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control study |
14 |
| The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis |
14 |
| Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group |
14 |
| The inflammatory response in the regression of lumbar disc herniation |
13 |
| Respiratory viral infections and the risk of rheumatoid arthritis |
13 |
| Age and fecal microbial strain-specific differences in patients with spondyloarthritis |
13 |
| A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis |
13 |
| Soluble uric acid increases PDZK1 and ABCG2 expression in human intestinal cell lines via the TLR4-NLRP3 inflammasome and PI3K/Akt signaling pathway |
13 |
| Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis |
13 |
| Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study |
13 |
| Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines |
12 |
| Proteomic and histopathological characterisation of sicca subjects and primary Sjogren's syndrome patients reveals promising tear, saliva and extracellular vesicle disease biomarkers |
12 |
| E2F2 directly regulates the STAT1 and PI3K/AKT/NF-kappa B pathways to exacerbate the inflammatory phenotype in rheumatoid arthritis synovial fibroblasts and mouse embryonic fibroblasts |
12 |
| Recombinant human proteoglycan-4 reduces phagocytosis of urate crystals and downstream nuclear factor kappa B and inflammasome activation and production of cytokines and chemokines in human and murine macrophages |
12 |
| Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse |
12 |
| Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes |
12 |
| Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial |
12 |
| Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study |
12 |
| Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 000 patients from Pharmachild and national registries |
12 |
| Musculoskeletal manifestations occur predominantly in patients with later-onset familial Mediterranean fever: Data from a multicenter, prospective national cohort study in Japan |
11 |
| Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus |
11 |
| Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy |
11 |
| A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy |
11 |
| High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus |
11 |
| Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations |
11 |
| Mice with miR-146a deficiency develop severe gouty arthritis via dysregulation of TRAF IRAK 1 and NALP3 inflammasome |
11 |
| Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONSER database |
11 |
| A comparative clinical study of PF-0641 a candidate adalimumab biosimilar, and adalimumab reference product (Humira (R)) in the treatment of active rheumatoid arthritis |
11 |
